BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/9/2025 1:05:43 PM | Browse: 26 | Download: 69
 |
Received |
|
2024-09-27 08:20 |
|
Peer-Review Started |
|
2024-08-08 12:02 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-11-18 09:09 |
|
Revised |
|
2024-12-02 04:51 |
|
Second Decision |
|
2025-02-05 02:45 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-02-06 08:40 |
|
Articles in Press |
|
2025-02-06 08:40 |
|
Publication Fee Transferred |
|
2024-12-31 06:51 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-02-24 01:15 |
|
Publish the Manuscript Online |
|
2025-04-09 13:05 |
| ISSN |
2220-6124 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Urology & Nephrology |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
Sucroferric oxyhydroxide monotherapy for hyperphosphatemia in Indian chronic kidney disease patients undergoing hemodialysis: A phase IV, single-arm, open-label study
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
M R Niranjan, Sanjay Srinivasa, Vibhanshu Gupta, Anil K Bhalla, Ankush Gaikwad, Prajakta Wangikar, Sachin Suryawanshi and Priti Gajbe |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Sanjay Srinivasa, MD, Department of Nephrology, Dr. Sanjay’s Center for Kidney and Diabetes, 357/B, Bangalore Bellary Road, Near to HDFC Bank, Yelahanka Town, Opposite RR Gold Palace, Bengaluru 560064, Karnātaka, India. drsanjay.nephro@gmail.com |
| Key Words |
Chronic kidney disease; Dynulta™; Hemodialysis; Hyperphosphatemia; Iron-based phosphate binder; Sucroferric oxyhydroxide |
| Core Tip |
This is the first research study on the use of Sucroferric oxyhydroxide (SO) in Indian patients and also marks the first such study from the Southeast Asia region. The study was a single-arm study, registered with the Clinical Trials Registry India. The positive results from this study will add to the growing body of evidence, primarily generated in the United States and European Union, supporting the efficacy of SO in the Asian population. |
| Publish Date |
2025-04-09 13:05 |
| Citation |
<p>Niranjan MR, Srinivasa S, Gupta V, Bhalla AK, Gaikwad A, Wangikar P, Suryawanshi S, Gajbe P. Sucroferric oxyhydroxide monotherapy for hyperphosphatemia in Indian chronic kidney disease patients undergoing hemodialysis: A phase IV, single-arm, open-label study. <i>World J Nephrol</i> 2025; 14(2): 100117</p> |
| URL |
https://www.wjgnet.com/2220-6124/full/v14/i2/100117.htm |
| DOI |
https://dx.doi.org/10.5527/wjn.v14.i2.100117 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
